Chemotherapy for Biliary Tract Cancer

Chemotherapy for Biliary Tract Cancer

The term of biliary tract cancer (BTC) refers to all tumors that arise from the biliary tract or the biliary drainage system, including the intra- and extra-hepatic bile ducts as well as the gallbladder. BTCs are aggressive tumors with limited treatment options and poor overall survival. Currently,...

Full description

Bibliographic Details
Main Author:	Sang Myung Woo
Format:	Article
Language:	English
Published:	Jin Publishing & Printing Co. 2017-03-01
Series:	The Korean Journal of Gastroenterology
Subjects:	Cholangiocarcinoma Chemotherapy
Online Access:	http://www.kjg.or.kr/journal/view.html?doi=10.4166/kjg.2017.69.3.172

Similar Items

Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients
by: Takeshi Okamoto, et al.
Published: (2023-07-01)

Chemotherapy for Biliary Tract Cancer in 2021
by: Takashi Sasaki, et al.
Published: (2021-07-01)

Current progress in perioperative chemotherapy for biliary tract cancer
by: Tatsuya Ioka, et al.
Published: (2023-07-01)

Biliary Tract Cancer: Current Medical Treatment Strategies
by: Ester Oneda, et al.
Published: (2020-05-01)

Research Progress of Biliary Tract Cancers
by: Lionel Aurelien A. Kankeu Fonkoua, et al.
Published: (2021-02-01)

Main causes of death in advanced biliary tract cancer
by: Kana Kimura‐Seto, et al.
Published: (2023-05-01)

Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
by: Alessandro Rizzo, et al.
Published: (2022-10-01)

Exploring the Promise of Second-Line Chemotherapy in Biliary Tract Tumours: A Glimpse into Novel Treatment Approaches
by: Paula Villalba Cuesta, et al.
Published: (2023-11-01)

A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada
by: Carissa Beaulieu, et al.
Published: (2021-01-01)

Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer
by: Felix Thol, et al.
Published: (2022-03-01)

Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas—A Relatively Rare Component of Biliary Tract Cancers in India
by: Prabhat G. Bhargava, et al.
Published: (2020-10-01)

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
by: Alessandro Rizzo, et al.
Published: (2022-01-01)

Somatic Mutations from Whole Exome Sequencing Analysis of the Patients with Biliary Tract Cancer
by: Kyong-Ah Yoon, et al.
Published: (2018-12-01)

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
by: Changhoon Yoo, et al.
Published: (2021-04-01)

Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza
by: Marcello Moro Queiroz, et al.
Published: (2023-03-01)

Current options and future directions of systemic therapy for advanced biliary tract cancer
by: Maria Giuseppina Prete, et al.
Published: (2021-10-01)

Adjuvant chemotherapy combined with immunotherapy in patients with cholangiocarcinoma after radical resection
by: Xiao‐hui Li, et al.
Published: (2023-12-01)

Real‐world outcomes among patients with advanced or metastatic biliary tract cancers initiating second‐line treatment
by: David P. Cosgrove, et al.
Published: (2023-02-01)

Epidemiologic patterns of biliary tract cancer in the United States: 2001–2015
by: Jill Koshiol, et al.
Published: (2022-11-01)

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
by: Sang Hoon Lee, et al.
Published: (2020-06-01)

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study
by: Monica Niger, et al.
Published: (2024-04-01)

Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
by: Alice Markussen, et al.
Published: (2020-07-01)

Efficacy and safety comparison of neoadjuvant chemotherapy followed by surgery and upfront surgery for treating intrahepatic cholangiocarcinoma: a systematic review and meta-analysis
by: Zijiao Yang, et al.
Published: (2023-04-01)

Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer
by: Haipeng Yu, et al.
Published: (2022-08-01)

The epidemiological trends of biliary tract cancers in the United States of America
by: Yong Jiang, et al.
Published: (2022-12-01)

Immunotherapy in Advanced Biliary Tract Cancers
by: Alice Boilève, et al.
Published: (2021-03-01)

Imaging of malignancies of the biliary tract- an update
by: Tiffany Priyanthi Hennedige, et al.
Published: (2014-04-01)

Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report
by: Roberta Marciano, et al.
Published: (2017-09-01)

Interplay between the Human Microbiome and Biliary Tract Cancer: Implications for Pathogenesis and Therapy
by: Cheng Ye, et al.
Published: (2023-10-01)

Genomics driven precision oncology in advanced biliary tract cancer improves survival
by: Chandan Kumar-Sinha, et al.
Published: (2023-08-01)

Insulin therapy and biliary tract cancer: insights from real-world data
by: Xiaohui Qi, et al.
Published: (2022-03-01)

A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
by: Ayhan Ulusakarya, et al.
Published: (2020-06-01)

First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!”
by: Alessandro Rizzo, et al.
Published: (2021-01-01)

Metabolomics of Duodenal Juice for Biliary Tract Cancer Diagnosis
by: Kazuma Kishi, et al.
Published: (2023-09-01)

Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
by: Ingrid Garajová, et al.
Published: (2023-11-01)

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
by: L. Perkhofer, et al.
Published: (2019-10-01)

Precision Oncology Targets in Biliary Tract Cancer
by: Nicole Farha, et al.
Published: (2023-03-01)

Robotic Surgery for Biliary Tract Cancer
by: Lyonell B. Kone, et al.
Published: (2022-02-01)

Treatment Patterns and Survival in Locally Advanced or Metastatic Biliary Tract Cancer Using SEER Medicare Data
by: Mark D. Danese, et al.
Published: (2023-01-01)

Changing Landscape of Systemic Therapy in Biliary Tract Cancer
by: Edward Woods, et al.
Published: (2022-04-01)